Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
NCT00814073Phase 3Completed
- Sponsor
- AB Science
- Start
- Dec 2008
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of masitinib in indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), sponsored by AB Science. Started Dec 2008; status: completed.
02
Drugs
masitinib
03
Conditions
indolent systemic mastocytosis (ISM)smoldering systemic mastocytosis (SSM)
Beyond the preview
Go deeper on NCT00814073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814073.